참고문헌
- Taioli E, Wolf AS, Camacho-Rivera M, et al. Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients. PLoS One 2015;10:e0145039. https://doi.org/10.1371/journal.pone.0145039
- Kwak KM, Paek D, Hwang SS, Ju YS. Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033. PLoS One 2017;12:e0183404. https://doi.org/10.1371/journal.pone.0183404
- Cho BC, Feld R, Leighl N, et al. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma. J Thorac Oncol 2014;9:397-402. https://doi.org/10.1097/JTO.0000000000000078
- de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413-8. https://doi.org/10.1200/JCO.2008.17.5604
- Nelson DB, Rice DC, Niu J, et al. Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis. J Clin Oncol 2017;35:3354-62. https://doi.org/10.1200/JCO.2017.73.8401
- de Perrot M, Feld R, Leighl NB, et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2016;151:468-73. https://doi.org/10.1016/j.jtcvs.2015.09.129
- de Perrot M, Wu L, Wu M, Cho BC. Radiotherapy for the treatment of malignant pleural mesothelioma. Lancet Oncol 2017;18:e532-e542. https://doi.org/10.1016/S1470-2045(17)30459-X
- Abdel-Rahman O. Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma. Lung Cancer 2017;113:128-33. https://doi.org/10.1016/j.lungcan.2017.09.015
- Lindenmann J, Matzi V, Neuboeck N, et al. Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent? Interact Cardiovasc Thorac Surg 2013;16:237-43. https://doi.org/10.1093/icvts/ivs465
- Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-52. https://doi.org/10.1200/JCO.1998.16.1.145
- Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31. https://doi.org/10.1378/chest.113.3.723
- McCambridge AJ, Napolitano A, Mansfield AS, et al. Progress in the management of malignant pleural mesothelioma in 2017. J Thorac Oncol 2018;13:606-23. https://doi.org/10.1016/j.jtho.2018.02.021
- Chi A, Liao Z, Nguyen NP, et al. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. J Thorac Oncol 2011;6:1132-41. https://doi.org/10.1097/JTO.0b013e3182199819
- Kostron A, Friess M, Crameri O, et al. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2016;49:1516-23. https://doi.org/10.1093/ejcts/ezv398
- Jhavar S, Pruszynski J, Gowan A, Boyle T, Deb N, Patel M. Intensity modulated radiation therapy after extra-pleural pneumonectomy for malignant pleural mesothelioma is feasible without fatal pulmonary toxicity and provides good survival. Asia Pac J Clin Oncol 2018;14:e88-e94. https://doi.org/10.1111/ajco.12680
- Forster KM, Smythe WR, Starkschall G, et al. Intensitymodulated radiotherapy following extrapleural pneumonectomy for the t reatment of mal ignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys 2003;55:606-16. https://doi.org/10.1016/S0360-3016(02)04150-0
- Shaikh F, Zauderer MG, von Reibnitz D, et al. Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2017;12:993-1000. https://doi.org/10.1016/j.jtho.2017.02.026
- De La Maza L, Wu M, Wu L, et al. In situ vaccination after accelerated hypofractionated radiation and surgery in a mesothelioma mouse model. Clin Cancer Res 2017;23:5502-13. https://doi.org/10.1158/1078-0432.CCR-17-0438
- Murphy DJ, Gill RR. Overview of treatment related complications in malignant pleural mesothelioma. Ann Transl Med 2017;5:235. https://doi.org/10.21037/atm.2017.03.97
- Kao SC, Cheng YY, Williams M, et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J Thorac Oncol 2017;12:1421-33. https://doi.org/10.1016/j.jtho.2017.05.024
- Verma V, Ahern CA, Berlind CG, et al. National Cancer Database report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma. J Thorac Oncol 2017;12:1704-14. https://doi.org/10.1016/j.jtho.2017.08.012
- Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005;63:1045-52. https://doi.org/10.1016/j.ijrobp.2005.03.041
- Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-95. https://doi.org/10.1067/mtc.2001.116560
- Kimura T, Doi Y, Nakashima T, et al. Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy. J Radiat Res 2015;56:315-24. https://doi.org/10.1093/jrr/rru102
- Stahel RA, Riesterer O, Xyrafas A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 2015;16:1651-8. https://doi.org/10.1016/S1470-2045(15)00208-9
- Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-9. https://doi.org/10.1183/09031936.00039510
- Alley EW, Katz SI, Cengel KA, Simone CB 2nd. Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl Lung Cancer Res 2017;6:212-9.
- Tang C, Welsh JW, de Groot P, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res 2017;23:1388-96. https://doi.org/10.1158/1078-0432.CCR-16-1432